Search

Your search keyword '"Moss, Ronald B."' showing total 201 results
Start Over Author "Moss, Ronald B."
201 results on '"Moss, Ronald B."'

13. HIV-1-specific CD4 helper function in persons with chronic HIV-1 infection on antiviral drug therapy as measured by ELISPOT after treatment with an inactivated, gp120-depleted HIV-1 in incomplete Freund's adjuvant

Author

Moss, Ronald B., Webb, Erin, Giermakowska, Wieslawa K., Jensen, Fred C., Savary, Jay R., Wallace, Mark R., and Carlo, Dennis J.

Subjects
HIV infection -- Drug therapy, Health, Remune (Medication) -- Evaluation
Abstract

The HIV-1 immunogen Remune appears to activate T cells that produce interferon gamma, according to a study of 10 HIV patients. This constitutes the first AIDS treatment that may actually restore the immune system.

Published
2000

27. Effect of immunization with an inactivated gp120-depleted HIV-1 immunogen on beta-chemokine and cytokine production in subjects with HIV-1 infection

Author

Moss, Ronald B., Trauger, Richard J., Giermakowska, Wieslawa K., Turner, John L., Wallace, Mark R., Jensen, Fred C., Richieri, Steven P., Ferre, Francois, Daigle, Anne E., Duffy, Christopher, Theofan, Georgia, and Carlo, Dennis J.

Subjects
HIV infection -- Physiological aspects, AIDS vaccines -- Physiological aspects, Cytokines -- Measurement, Health
Abstract

Immunization with the HIV-1 immunogen REMUNE appears to induce T cell proliferation and the production of cytokines that can inhibit HIV. Researchers studied the production of a cytokine called RANTES and interferon-gamma production in blood samples from 15 HIV-infected patients who had been immunized with REMUNE. REMUNE stimulated interferon-gamma production and RANTES production. Immunization also seemed to control viral reproduction and stabilize CD4 T cell counts.

Published
1997

28. Early clinical markers and CD4 percentage in subjects with human immunodeficiency virus infection

Author

Wallace, Mark R., Moss, Ronald B., Beecham, H. James, III, Grace, Christopher J., Hersh, Evan M., Peterson, Eskild, Murphy, Robert, Shepp, David H., Siegal, Frederick P., Turner, John L., Safrin, Sharon, Carlo, Dennis J., and Levine, Alexandra M.

Subjects
CD4 lymphocytes -- Measurement, HIV infection -- Complications, Opportunistic infections -- Development and progression, Health
Abstract

There appears to be a relationship between early opportunistic infections in HIV patients and a drop in the percentage of CD4 cells. This was demonstrated in 103 HIV-infected patients who were receiving immunotherapy with an inactivated form of HIV. A drop in the percentage of CD4 cells occurred sooner and more rapidly in the patients who developed an early opportunistic infection such as oral Candida infection or oral hairy leukoplakia. Patients with the greatest decline had 5 times the risk of these infections.

Published
1996

29. Safety and immunogenicity of a gp120-depleted, inactivated HIV-1 immunogen: results of a double-blind, adjuvant controlled trial

Author

Trauger, Richard J., Diagle, Anne E., Giermankowska, Wieslawa, Moss, Ronald B., Jensen, Fred, and Carlo, Dennis J.

Subjects
HIV infection -- Drug therapy, Immunotherapy -- Evaluation, AIDS vaccines -- Evaluation, Health
Abstract

The use of a human immunodeficiency virus (HIV) immunization appears to be safe and moderately effective in stimulating an immune response in patients positive for HIV. Doctors immunized 103 HIV-positive patients who exhibited no symptoms with a series of either three immunizations containing deactivated HIV (treatment group) or three placebo immunizations (control group). Antibody levels rose in the patients receiving the HIV immunization with maximum levels occurring 8 weeks after the third injection. Six months after the third injection, antibody levels were similar for both groups. Measurements of immune response rose by 21% in the treatment while these measurements decreased by 28% in the control group. Most (78%) of the reported side effects were mild and occurred in both groups.

Published
1995

30. Viral load in peripheral blood mononuclear cells as surrogate for clinical progression

Author

Ferre, Francoise, Moss, Ronald B., Daigle, Anne, Richieri, Steven P., Jensen, Fred, and Carlo, Dennis J.

Subjects
Viral genetics -- Usage, HIV infection -- Development and progression, Viremia -- Measurement, Immunotherapy -- Evaluation, Health
Abstract

Measurements of human immunodeficiency virus (HIV) DNA or RNA levels in peripheral blood mononuclear cell samples may be useful in monitoring disease progression in patients with HIV. Researchers highlighted current studies that have used HIV DNA and RNA levels as indicators of disease progression and drug effectiveness. Patients with a rapid decline in CD4 cell counts seem to have significantly higher blood levels of HIV RNA and DNA as compared to patients with a slow decline in CD4 cell counts. However, the association between viral levels and disease progression may be independent of CD4 cell counts. One study found that patients with high blood levels of HIV DNA subsequently developed AIDS. Other studies have shown that blood levels of HIV DNA drop in conjunction with HIV drug therapies, such as didanosine and AZT, but subsequently rise in the months following treatment.

Published
1995

31. Inactivated HIV-1 Immunogen: impact on markers of disease progression

Author

Moss, Ronald B., Ferre, Francois, Trauger, Richard, Jensen, Fred, Daigle, Anne, Richieri, Steven P., and Carlo, Dennis J.

Subjects
HIV infection -- Development and progression, AIDS vaccines -- Evaluation, Health, HIV-1 Immunogen (Vaccine) -- Evaluation
Abstract

The Immune Response Corporation's HIV-1 Immunogen vaccine against HIV appears to have several positive effects on the immune systems of HIV-infected patients. The vaccine is made without the protein envelope that coats the virus and is made from completely inactive virus. It includes numerous proteins, which should help broaden its effectiveness. It also contains an additional medication, incomplete Freund's adjuvant (IFA), which boosts antibody production. In tests of 103 HIV-positive patients without symptoms, 51 were given the vaccine and 52 were given just IFA. The patients who received the vaccine had lower levels of HIV-1 DNA, a slight gain in lymphocytes that are produced by the immune system and a smaller decline in the percentage of CD4+ T cells. HIV-1 Immunogen causes few side effects; the main one is a reaction at the site of the injection. It is unknown whether the immunological improvements that appear to result from the vaccine will lead to better health for HIV-infected patients.

Published
1994

40. Spontaneous and antigen-induced production of HIV-inhibitory [Beta]-chemokines are associated with AIDS-free status

Author

Garzino-Demo, Alfredo, Moss, Ronald B., Margolick, Joseph B., Cleghorn, Farley, Sill, Anne, Blattner, William A., Cocchi, Fiorenza, Carlo, Dennis J., DeVico, Anthony L., and Gallo, Robert C.

Subjects
HIV (Viruses) -- Care and treatment, AIDS (Disease) -- Care and treatment, Cytokines -- Research, HIV antigens -- Research, Science and technology
Abstract

The [Beta]-chemokines RANTES, macrophage inflammatory protein (MIP)-1[Alpha], and MIP-1[Beta] suppress infection by macrophage-tropic strains of HIV and simian immunodeficiency virus (SIV) by binding and down-regulating the viral coreceptor, CCR5. Accordingly, we have examined whether higher levels of CCR5 ligands are associated with a more favorable clinical status in AIDS. A cross-sectional study of 100 subjects enrolled in the Multicenter AIDS Cohort Study at the Baltimore site was conducted to measure chemokine production and lymphocyte proliferation by peripheral blood mononuclear cells (PBMC). Statistical analyses of the data revealed that the production of HIV-suppressive [Beta]-chemokines by HIV antigen-stimulated PBMC was significantly higher in HIV-positive subjects without AIDS compared with subjects with clinical AIDS. Increased chemokine production was also correlated with higher proliferative responses to HIV antigens. Both parameters were significantly lower in the AIDS versus non-AIDS group. Notably, significantly higher levels of MIP-1[Alpha] were also observed with unstimulated PBMC from seronegative subjects at risk for HIV infection released as compared with seropositive and non-Multicenter AIDS Cohort Study seronegative subjects. The association of chemokine production with antigen-induced proliferative responses, more favorable clinical status in HIV infection, as well as with an uninfected status in subjects at risk for infection suggests a positive role for these molecules in controlling the natural course of HIV infection. lymphocyte proliferation

Published
1999

42. Perspective: Emerging Challenges in the Treatment of Influenza and Parainfluenza in Transplant Patients

Author

Moss, Ronald B., Steigbigel, Roy T., Sanders, Rebecca L., and Fang, Fang

Subjects
Article Subject, viruses, virus diseases
Abstract

Influenza, respiratory synctial virus, and parainfluenza are common respiratory infections in immunocompromised transplant recipients, causing significant morbidity and mortality in this patient population. This paper focuses on influenza and parainfluenza virus infections in transplant patients with emphasis on the pandemic 2009 H1N1 influenza infection. Current antiviral treatment recommendations for influenza and parainfluenza in immunocompromised patients as well as novel investigational therapeutic approaches currently being tested in the clinic are discussed. In addition to the morbidity and mortality caused by these viruses, the development of multidrug resistance leading to transmission of resistant viruses is of great public health concern. The development of effective new therapies for influenza and parainfluenza in these high-risk patients is needed with randomized placebo-controlled studies to assess their clinical utility.

Published
2011
Full Text
View/download PDF

45. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin

Author

Smith, Larry R., primary, Wloch, Mary K., additional, Ye, Ming, additional, Reyes, Luane R., additional, Boutsaboualoy, Souphaphone, additional, Dunne, Casey E., additional, Chaplin, Jennifer A., additional, Rusalov, Denis, additional, Rolland, Alain P., additional, Fisher, Cindy L., additional, Al-Ibrahim, Mohamed S., additional, Kabongo, Martin L., additional, Steigbigel, Roy, additional, Belshe, Robert B., additional, Kitt, Ernest R., additional, Chu, Alice H., additional, and Moss, Ronald B., additional

Published
2010
Full Text
View/download PDF

47. Novel Pandemic Influenza A(H1N1) Viruses Are Potently Inhibited by DAS181, a Sialidase Fusion Protein

Author

Triana-Baltzer, Gallen B., primary, Gubareva, Larisa V., additional, Nicholls, John M., additional, Pearce, Melissa B., additional, Mishin, Vasiliy P., additional, Belser, Jessica A., additional, Chen, Li-Mei, additional, Chan, Renee W. Y., additional, Chan, Michael C. W., additional, Hedlund, Maria, additional, Larson, Jeffrey L., additional, Moss, Ronald B., additional, Katz, Jacqueline M., additional, Tumpey, Terrence M., additional, and Fang, Fang, additional

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results